Angiostatin and anti-angiogenic therapy in human disease

Recent Progress in Hormone Research

Volumn 59, Issue , 2004, Pages 73-104

  Wahl, Miriam L ^a   Moser, Tammy L ^a   Pizzo, Salvatore V ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN;

ANGIOGENESIS; CANCER; CANCER CELL; CLINICAL FEATURE; DIABETES MELLITUS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; TUMOR GROWTH; VASCULARIZATION; ANIMAL; CHEMISTRY; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOSTATINS; ANIMALS; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 2342431195     PISSN: 00799963     EISSN: None     Source Type: Journal    
DOI: 10.1210/rp.59.1.73     Document Type: Review

References (190)

1. Agarwala SS, Kirkwood JM 2003 Temozolomide in combination with interferon α-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer 97:121-127
2. Agius E, Sagot Y, Duprat AM, Cochard P 1996 Antibodies directed against the β1-integrin subunit and peptides containing the IKVAV sequence of laminin perturb neurite outgrowth of peripheral neurons on immature spinal cord substrata. Neuroscience 71:773-786
3. FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 105:104-108
4. + exchanger isoform NHE3. Am J Physiol 276:C136-C144
5. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124
6. Allt G, Lawrenson JG 2001 Pericytes: cell biology and pathology. Cells Tiss Organs 169:1-11
7. Aoudjit F, Vuori K 2001 Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol 152:633-643
8. +-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells (HUVECs). Mol Cancer Res 1:931-939
9. Baatout S, Cheta N 1996 Matrigel: a useful tool to study endothelial differentiation. Rom J Intern Med 34:263-269
10. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF 2000 Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710-2717
11. Barinaga M 1995 Shedding light on blindness. Science 267:452-453
12. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DB, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J 2002 Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302
13. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E 2002 Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13:1259-1263
14. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL 2001 Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262-5257
15. Beltramo E, Buttiglieri S, Pomero F, Allione A, D'Alu F, Ponte E, Porta M 2003 A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia 46:409-415
16. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini A 2002 Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16:267-269
17. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1277-1280
18. Bhargava P, Marshall JL, Bahut W, Rizvi N, Tocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ 2001 A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin. Cancer Res 7:3912-3919
19. Bier H, Reiffen KA, Haas I, Stasiecki P 1995 Dose-dependent access of omurine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 252:433-439
20. Boyer MJ, Tannock IF 1992 Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res 52:4441-4447
21. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL 2000 A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 6:4697-4704
22. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD 2000 Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6:1-10
23. Brivio F, Lissoni P, Rovelli F, Nespoli A, Uggeri F, Fumagalli L, Gardani G 2002 Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49:385-387
24. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW 1996 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943
25. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W 2001 Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Intl J Radiat Oncol Biol Phys 51:349-353
26. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS 2003 Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802-811
27. Burd R, Wachsberger PR, Biaglow JE, Wahl ML, Leeper DB 2001 Absence of Crabtree effect in human melanoma cells adapted to growth at low pH: reversal by respiratory inhibitors. Cancer Res 61:5630-5635
28. Canfield AE, Schor AM, Schor SL, Grant ME 1986 The biosynthesis of extracellular-matrix components by bovine retinal endothelial cells displaying distinctive morphological phenotypes. Biochem J 235:375-383
29. Cao Y, Veitonmaki N, Keough K, Cheng H, Lee LS, Zurakowski D 2000 Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Intl J Mol Med 5:547-551
30. Cascone I, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F 2003 Tie-2-dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood 102:2482-2490
31. Chen HX, Gore-Langton RE, Cheson BD 2001 Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 15:1017-1026
32. Chu G, Dewey WC 1988 The role of low intracellular or extracellular pH in sensitization to hyperthermia. Radiat Res 114:154-167
33. Chu GL, Wang Z, Hyun W, Pershadingh H, Fulwyler M, Dewey WC 1990 The role of intracellular pH and its variance in low pH sensitization of killing by hyperthermia. Radiat Res 122:288-293
34. Claesson-Welsh L, Welsh M, Ito N, Ananda-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J 1998 Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 95:5579-5583
35. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R 2000 Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 1:2520-2526
36. Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC 1996 Integrin α3β1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell 7:1789-1804
37. Craighead JE 1994 Diabetes. In: Rubin E, Farber J, eds. Pathology, chap 22. Philadelphia: J.B. Lippincott Co.; 1148-1160
38. Daliani DD, Papandreous CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R 2002 A pilot study of thalidomide therapy in refractory solid tumour patients. Cancer 95:758-765
39. D'Amato RJ, Loughnan MS, Flynn E, Folkman J 1994 Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
40. Danielsen T, Rofstad EK 2000 The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 82:1528-1534
41. Danis RP, Ciulla TA, Criswell M, Pratt L 2001 Anti-angiogenic therapy of proliferative diabetic retinopathy. Expert Opin Pharmacother 2:395-407
42. DCCT Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
43. th Annual Meeting of the American Society for Clinical Oncology. May 12-15, San Francisco, abstract 10
44. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ 1998 Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α adminstration. Cancer Res 58:808-814
45. Drasdo N, Chiti Z, Owens DR, North RV 2002 Effect of darkness on inner retinal hypoxia in diabetes. Lancet 359:2251-2253
46. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM 1988 Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109
47. Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD 1996 A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 7:491-496
48. Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK 1999 Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 17:1095-1104
49. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J 2002 Phase I clinical trial of recombinant human ednostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772-3784
50. Egginton S, Zhou AL, Brown MD, Hudlicka O 2000 The role of pericytes in controlling angiogenesis in vivo. Adv Exp Med Biol 476:81-99
51. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y 2003 Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 100:6033-6038
52. Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD 1995 Extracellular pH distribution in human tumours. Intl J Hyperthermia 11:211-216
53. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60:712-721
54. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ 2003 Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 536:19-24
55. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A 2002 Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029-1035
56. Facchiano F, Lentini A, Fogliano V, Mancarella S, Rossi C, Facchiano A, Capogrossi MC 2002 Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. Am J Pathol 161:531-541
57. Fett JW, Strydom DJ, Lubb RR, Adlerman EM, Bethune JL, Riordan JF, Vallee BL 1985 Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480-5486
58. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marme D, Augustin HG 2003 Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278:1721-1727
59. Fife CE, Buyukcakir C, Otto GH, Sheffield PJ, Warriner RA, Love TL, Mader J 2002 The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1,144 patients. Wound Repair Regen 10:198-207
60. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL 2001 A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28:62-66
61. Folkman J 1971 Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
62. th Annual Meeting of the American Society for Clinical Oncology. May 12-15, San Francisco, abstract 2144
63. Fruhstorfer B 2000 Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology. Internist (Berl) 41:A38
64. Funatsu H, Yamashita H, Noma H, Shimizu E, Mimura T, Hori S 2002 Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 28:1355
65. Funatsu H, Yamashita H, Noma H, Mochizuki H, Mimura T, Ikeda T, Hori S 2003 Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci 44:1042-1047
66. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR 2002 Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840
67. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA 1996 Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56:4887-4890
68. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL 2001 Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61:7992-7998
69. Gonzalez-Gronow M, Grenert HM, Fuller GM, Pizzo SV 1990 The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in E. coli and COS cells. Biochim Biophys Acta 1039:269-274
70. Gonzalez-Gronow M, Kalfa T, Johnson CE, Gawdi G, Pizzo SV 2003 The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. J Biol Chem 278:27312-27318
71. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D 2001 Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
72. Grant DS, Kleinman HK 1997 Regulation of capillary formation by laminin and other components of the extracellular matrix. Experientia (suppl)79:317-333
73. Grant DS, Zukowska Z 2000 Revascularization of ischemic tissues with SIKVAV and neuropeptide Y (NPY). Adv Exper Med Biol 476:139-154
74. Grant DS, Kleinman HK, Martin GR 1990 The role of basement membranes in vascular development. Ann NY Acad Sci 588:61-72
75. Grant DS, Kinsella JL, Kibbey MC, LaFlamme S, Burbelo PD, Goldstein AL, Kleinman HK 1995 Matrigel induces thymosin β4 gene in differentiating endothelial cells. J Cell Sci 108:3685-3694
76. + antiport: assessment of effect on intracellular pH. EMBO J 12:5209-5218
77. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG 2003 Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 162:1431-1439
78. Gullege CJ, Dewhirst MW 1996 Tumor oxygenation: a matter of supply and demand. Anticancer Res 16:741-749
79. Gutheil J, Finucane D 2002 Thalidomide therapy in refractory solid tumour patients. Br J Haematol 110:754
80. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA 2000 Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αv-β3. Clin Cancer Res 6:3056-3061
81. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A 2002 The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16:1802-1804
82. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U 2002 Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107-3112
83. Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
84. Heath EI, O'Reilly S, Humphreys R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carduccim MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB 2001 Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48:269-274
85. 2 gradients in solid tumor In vivo: high-resolution measurements reveal a lack of correlation. Nature Med 3:177-182
86. Helminger G, Sckell A, Dellian M, Forbes NS, Jain RK 2002 Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284-1291
87. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW 2002a Development of biological markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814
88. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW 2002b Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803
89. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Basela J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM 2002c Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815-3825
90. Hillman N, Cox S, Noble AR, Gallagher PJ 2001 Increased numbers of caveolae in retinal endothelium and pericytes in hypertensive diabetic rats. Eye 15:319-325
91. Humphries MJ, Oldern K, Yamada KM 1986 A synthetic peptide from fibronectin inhibits experimental metastasis in murine melanoma cells. Science 233:467-470
92. Jayson GC, Zweit J, Jackson C, Mlulatero C, Julyan P, Ranson M, Broughton I, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H 2002 Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484-1493
93. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J 1999 Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics 103:1145-1149
94. Kalfa T, Gerritsen M, Carlson E, Binstock A, Tsilibary E 1995 Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Visual Sci 36:2358-2367
95. Kallinowski F, Vaupel P, Runkel S, Berg G, Fortmeyer HP, Baessler KH, Wagner K, Mueller-Klieser W, Walenta S 1988 Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 48:7264-7272
96. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S 2003 Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 94: 43-49
97. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW 1996 Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522-5528
98. Knott RM, Robertson M, Muckersie E, Folefac VA, Fairhurst FE, Wileman SM, Forrester JV 1999 A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia 42:870-877
99. Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Botstick-Bruton F, Kulpha V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA 2001 A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 7:1600-1609
100. Koslowski M, Tureci O, Bell C, Krause P, Lehr HA, Brunner J, Seitz G, Nestle FO, Huber C, Sahin U 2002 Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res 62:6750-6755
101. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL 2001 Hypoxia-regulated carbonic anhydrase-9 (CA-9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403
102. Kubota Y, Kleinman HK, Martin GR, Lawley TJ 1988 Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107:1589-1598
103. Lakhani NJ, Sarkar MA, Venitz J, Figg WD 2003 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165-172
104. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant DS, Zukowska Z 2003 Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 111:1853-1862
105. Leeper DB, Engin K, Wang JH, Cater JR, Li DJ 1994 Human tumor extracellular pH as a function of blood glucose concentration. Intl J Radiat Oncol Biol Physics 28:935-943
106. Leeper DB, Engin K, Wang GJ, Li DJ 1998 Effect of i.v. oral glucose on human tumour extracellular pH for potential sensitization to thermoradiotherapy. Intl J Hyperthermia 14:257-269
107. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J 2001 Phase I and pharmacological study of the oral matrix metalloproteinase inhibitors, MM1270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912-1922
108. Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, Ellis LM 2000 Endothelial cell survival and apoptosis in the tumor. Apoptosis 5:323-328
109. Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, Hurwitz HI 2003 Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 9:586-593
110. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU 2001 Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198-1203
111. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS 1998 Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92:4730-4741
112. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P 2003 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375
113. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA 1992 Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340:145-146
114. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM 2002 Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 105:2185-2191
115. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR 1998 Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature Rev Cancer 394:287-291
116. McDonald DM, Baluk P 2002 Significance of blood vessel leakiness in cancer. Cancer Res 62:5381-5385
117. McSwine RL, Babnigg G, Musch MW, Change EB, Villereal ML 1994 Expression and phosphorylation of NHE1 in wild-type and transformed human and rodent fibroblasts. J Cell Physiol 161:351-357
118. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV 1999 Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96:2811-2816
119. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misro UK, Cheek DJ, Pizzo S 2001 Endothelial cell surface F1-Fo ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 98:6656-6661
120. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelze F, Chappell R, Neider R, Sebree LA, Friedl A 2001 Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7:3366-3374
121. Muthukkaruppan VR, Auerback R 1970 Angiogenesis in the mouse cornea. Science 205:1416-1418
122. Newell K, Franchi A, Pouyssegur J, Tannock IF 1993 Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90:1127-1131
123. Nicosia RF, Ottinetti A 1990 Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 63:115-122
124. Nicosia RF, Tuszynski GP 1994 Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 124:183-193
125. Nicosia RF, Nicosia SV, Smith M 1994 Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 145:1023-1029
126. Noma H, Funatsu H, Yamashita H, Kitano S, Mishima HK, Hori S 2002 Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 120:1075-1080
127. Oates PJ 2002 Polyol pathway and diabetic peripheral neuropathy. Intl Rev Neurobiol. 50:325-392
128. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ 2001 Carbonic anhydrase 9 as an endogenous marker for hypoxic cell in cervical cancer. Cancer Res 61:8924-8929
129. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J 1994a Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328
130. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J 1994b Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harbor Symp Quant Biol 59:471-482
131. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell Physiol Biochem 88:277-285
132. OSI Pharmaceuticals, Genentech, Roche 2001 OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva. Expert Rev Anticancer Ther 1:4-5
133. Ossowski L, Reich E 1983 Antibodies to plasminogen activator inhibit tumor metastasis. Cell 88:611-619
134. Owen CS, Pooler PM, Wahl ML, Bobyock SB, Coss RA, Leeper DB 1997 Altered proton extrusion in cells adapted to growth at low extracellular pH. J Cell Physiol 173:397-405
135. Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber DE, Wang N 1997 Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J Cell Sci 110:1091-1098
136. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF 2003 A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9:1323-1332
137. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK 2002 ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240-2250
138. Reber F, Gersch U, Funk RW 2003 Blockers of carbonic anhydrase can cause increase of retinal capillary diameter, decrease of extracellular and increase of intracellular pH in rat retinal organ culture. Graefes Arch Clin Exp Ophthalmol 241:140-148
139. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD 2003 Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9:1666-1672
140. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S 2002 Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 62:789-795
141. Ries M, Basseau F, Tyndal B, Jones R, Deminiere C, Catargi B, Combe C, Moonen CW, Grenier N 2003 Renal diffusion and BOLD MRI in experimental diabetic nephropathy. J Magnet Reson Imag 17:104-113
142. Risau W, Lemmon V 1988 Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125:441-450
143. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleli MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW 2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243
144. Roskelley CD, Bissell MJ 2002 The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 12:97-104
145. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E 2001 Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 19:584-592
146. Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, Bellon L, Usman N, Rossing T, Borden E, Blatt LM 2000 Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 40:1462-1469
147. Schober T, Bilzer T, Waha A, Reifenberger G, Wechsler W, Dieimling A, Wiestler OD, Westphal M, Kemshead JT, Vega F 1995 The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 14:169-174
148. vβ1, independent of cell shape. Proc Natl Acad Sci USA 88:7849-7853
149. Schwartz MA, Ingber DE, Lawrence M, Springer TA, Lechene C 1991b Multiple integrins share the ability to induce elevation of intracellular pH. Exp Cell Res 195:533-535
150. Secomb TW, Hsu R, Dewhirst MW, Klitzman B, Gross JF 1993 Analysis of oxygen transport to tumor tissue by microvascular networks. Intl J Radiat Oncol Biol Phys 25:481-489
151. Sennlaub F, Valamanesh F, Vazquez-Tello A, El-Asrar AM, Checchin D, Brault S, Gobeil F, Beauchamp MH, Mwaikambo B, Courtois Y, Geboes K, Varma DR, Lachapelle P, Ong H, Behar-Cohen F, Chemtob S 2003 Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108:198-204
152. Shan S, Sorg B, Dewhirst MW 2003 A novel rodent mammary window of orthotopic breast cancer for intravital microscopy. Microvasc Res 65:109-117
153. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S 2002 Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439
154. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M 2001 Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 51:41-45
155. Soff GA, Hong J, Fishman D, Schultz R, Cundiff DL, Park S, Enghild JJ, Stack MS, Gately S 1999 Angiostatin 4.5: a naturally occurring human angiogenesis inhibitor. Proc Am Assoc Cancer Res 40:4088
156. Sood AK, Gupta B, Chugh P 1999 Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits. Meth Findings Exp Clin Pharmacol 21:491-497
157. Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF 2000 Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 43:1404-1407
158. Stopeck AM, Sheldon M, Vahedian G, Cropp R, Gosalia R, Hannah A 2002 Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798-2805
159. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R 2003 Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 100:4766-4771
160. Swinson DE, Jones JL, Richardson D, Wykoff CC, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ 2003 Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with poor prognosis in non-small cell lung cancer. J Clin Oncol 21:473-482
161. 3 in endothelial cells. J Biol Chem 276:39562-29567
162. te Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel RI 2002 Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 89:1302-1309
163. Thews O, Kelleher DK, Esser N, Kraus S, Vaupel P 2003 Lack of association between tumor hypoxia, GLUT-1 expression and glucose uptake in experimental sarcomas. Adv Exp Med Biol 510:57-61
164. Thistlethwaite AJ, Alexander GA, Moylan DJ, Leeper DB 1987 Modification of human tumor pH by elevation of blood glucose. Intl J Radiat Oncol Biol Physics 13:603-610
165. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A 2003 Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223-231
166. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L 2001 Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247-1254
167. Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS 2000 Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 18:716-723
168. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, Brasch RC 2002 MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 9(suppl 2):S519-S520
169. van Hinsbergh VW, Collen A, Koolwijk P 2001 Role of fibrin matrix in angiogenesis. Ann NY Acad Sci 936:426-437
170. Vassalli J-D, Appino A-P, Belin D 1991 The plasminogen activator/plasmin system. J Clin Invest 88:1067-1072
171. Vaupel P 1997 Blood flow and oxygenation status of head and neck carcinomas. Adv Exp Med Biol 428:89-95
172. Vaupel P, Kallinowski F, Okunieff P 1989 Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449-6465
173. Vaupel P, Thews O, Kelleher DK, Hoeckel M 1998 Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Adv Exp Med Biol 454:591-602
174. Verstappen CC, Postma TJ, Hoekman K, Heimans JJ 2003 Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer. J Neurooncol 63:201-205
175. Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D, Leeper DB 2002 Variability in glucose transporter 1 levels and hexokinase activity in human melanoma. Melanoma Res 12:35-43
176. Wahl ML, Grant DS 2002 Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. J Gen Pharm (Vascular) 35:1-10
177. Wahl ML, Coss RA, Bobyock SB, Leeper DB, Owen CS 1996 Thermotolerance and intracellular pH in two Chinese hamster cell lines adapted to growth at low pH. J Cell Physiol 166:438-445
178. nd Annual Meeting of the American Association for Cancer Research. New Orleans, abstract 27, p 5
179. Wahl ML, Owen CS, Grant DS 2002a Low dose angiostatin induces intracellular acidosis and anoikis cell death in endothelial cells at tumor-like low pH. Endothelium 9:205-216
180. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS 2002b Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617-628
181. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W 1997 Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 150:409-415
182. Walter JJ, Sane DC 1999 Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arterioscler Thromb Vasc Biol 19:2041-2048
183. Weidner N, Semple JP, Welch WR, Folkman J 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8
184. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J 1993 Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:410-409
185. Whatmore JL, Swann E, Barraja P, Newsome JJ, Bunderson M, Beall HD, Tooke JE, Moody CJ 2002 Comparative study of isoflavone, quinoxaline and oxindole families of antiangiogenic agents. Angiogenesis 5:45-51
186. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger B 2003 Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 100:5028-5033
187. Yamagata M, Tannock IF 1996 The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer 73:1328-1334
188. Yegutikin GG, Henttinen T, Samburski SS, Spychala J, Jalkanen S 2002 The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem J 367:121-128
189. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S 2000 Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196
190. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G 2003 Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63:3403-3412